14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:DPRX
Delisted

Dipexium Pharmaceuticals Fund Forecast

$1.34
+0 (+0%)
At Close: Jan 16, 2018
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.

FAQ

What is the symbol for Dipexium Pharmaceuticals Fund and on which exchange is it traded?
The symbol for Dipexium Pharmaceuticals is DPRX and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Dipexium Pharmaceuticals Fund?
Dipexium Pharmaceuticals holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

How to buy Dipexium Pharmaceuticals Fund?
Dipexium Pharmaceuticals Fund can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Dipexium Pharmaceuticals Fund.

What's the current price of Dipexium Pharmaceuticals Fund?
As of the end of day on the Jan 16, 2018, the price of an Dipexium Pharmaceuticals (DPRX) share was $1.34.

What is the 52-week high and low for Dipexium Pharmaceuticals Fund?
The 52-week high for Dipexium Pharmaceuticals Fund is $1.60 and the 52-week low is $1.05.
Click to get the best stock tips daily for free!

About Dipexium Pharmaceuticals

Dipexium Pharmaceuticals, Inc., a late stage pharmaceutical company, focuses on the development and commercialization of antibiotics in the United States. It develops Locilex (pexiganan cream 0.8%), a novel, broad spectrum, and topical antibiotic, which is in Phase 3 clinical trials for the treatment of mild infections of diabetic foot ulcers. The company was founded in 2010 and is based in New York, New York.... DPRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT